A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT (NORTH)
A Phase II Study of Panobinostat in Pediatric, Adolescent and Young Adult Patients With Solid Tumors Including Osteosarcoma, Malignant Rhabdoid Tumor/Atypical Teratoid Rhabdoid Tumors and Neuroblastoma
Sponsor: Australian & New Zealand Children's Haematology/Oncology Group
Terminated
Drug supply
Listed as NCT04897880, this PHASE2 trial focuses on Atypical Teratoid/Rhabdoid Tumor and Malignant Rhabdoid Tumor and remains terminated or withdrawn. Sponsored by Australian & New Zealand Children's Haematology/Oncology Group, it has been updated 7 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Mar 2025 — Present [monthly]
Terminated PHASE2
-
Oct 2024 — Mar 2025 [monthly]
Terminated PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
▶ Show 2 earlier versions
-
Sep 2021 — Jul 2022 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
First recorded
Jan 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Australian & New Zealand Children's Haematology/Oncology Group
- National Health and Medical Research Council, Australia
- Secura Bio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .